NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=150507&from=4CLASS PERI ...

NEW YORK CITY and NEW ORLEANS, May 27, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pen ...

公司动态 - Iovance Biotherapeutics是一家商业阶段生物制药公司 专注于开发和商业化用于治疗转移性黑色素瘤和其他实体瘤癌症的细胞疗法 [1] - 公司2025年第一季度总产品收入为4930万美元 较上一季度的7370万美元显著下降 [3] - 公司将2025财年总产品收入指引从4.5亿-4.75亿美元大幅下调至2.5亿-3亿美元 中值降幅超过40% [3] - 公司股价在2025年5月9日下跌1.42美元 跌幅达44.8% 收盘价为1.75美元 [3] 产品与销售情况 - 公司主要产品Amtagvi在授权治疗中心(ATCs)面临患者治疗启动时间延长的问题 [2] - 销售团队和新ATCs在患者识别和选择方面效率低下 导致患者流失率上升 [2] - ATCs无法跟上产品制造速度 导致成本上升和收入下降 [2] 法律诉讼 - 股东集体诉讼指控公司在2024年5月9日至2025年5月8日期间误导投资者 [1] - 诉讼称公司未披露ATCs运营问题和销售团队效率低下等负面信息 [2] - 公司对业务前景的积极陈述被认为具有重大误导性或缺乏合理依据 [2]

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts clai ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Iovance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 8, 2025 ...

NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts clai ...

LOS ANGELES, May 23, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CLICK HERE BEFORE JULY 14, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed ...

公司动态 - Iovance Biotherapeutics因涉嫌违反联邦证券法被调查 公司及高管被指控发布虚假或误导性声明 未披露其真实增长潜力及市场需求承接能力不足的问题 [5] - 2024年7月25日公司发布2024年第二季度财报 同时下调全年营收指引 归因于iCTC设备年度维护导致产能减半 Proleukin销售不及预期及治疗中心患者收治节奏不稳定 [6] - 2025年5月9日公司股价单日暴跌44.795% 从5月8日收盘价3.17美元/股跌至1.75美元/股 直接触发投资者集体诉讼 [6] 法律进展 - 联邦证券集体诉讼案已立案 投资者需在2025年7月14日前申请成为首席原告 [3] - 律师事务所Faruqi & Faruqi主导调查 该机构自1995年起累计为投资者追回数亿美元损失 [4] - 潜在信息提供者包括内部举报人、前员工及股东 可匿名提交证据 [8] 投资者行动 - 损失超10万美元的投资者可联系律所合伙人Josh Wilson商讨法律救济方案 联系电话877-247-4292或212-983-9330分机1310 [1][9] - 首席原告需为索赔金额最大且能代表集体诉讼成员的适格投资者 [7]